Mayer Brown announced today that it represented Adaptimmune Therapeutics PLC on its approximately $191.3 million initial public offering, advising the company on all aspects of US and UK corporate and securities laws and related disciplines. Adaptimmune is a clinical stage biopharmaceutical company focused on novel cancer immunotherapy products based on its T-cell receptor platform.
In 2014, Mayer Brown represented Adaptimmune Limited
on its $104 million Series A financing round led by a group of leading public and private healthcare focused venture funds and leading mutual funds, including New Enterprise Associates, OrbiMed, Fidelity and Wellington, marking one of the largest Series A biopharmaceutical investment rounds in history.
The Mayer Brown team was led by Corporate & Securities partner David Bakst (New York) and included: Corporate & Securities partner Richard Smith (London) and associates Mandee Lee, George Rudy, Stephanie Grajales (all New York) and Megan Paul (London); Tax Transactions & Consulting partners James Hill (London) and Jason Bazar and associate Moe Worsley (both New York); Employment & Benefits partners Andrew Stanger (London) and James Williams (Chicago); Intellectual Property partner Rich Assmus (Chicago) and associate Neil DuChez (New York); and Litigation & Dispute Resolution partner Elizabeth Mann (Los Angeles).